Metraipolis › archive › dc_28e696b09cc3
Observational study of haloperidol in hospitalized patients with COVID-19 — Europe PMC PMID:33606790
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/33606790
- DOI
- 10.1371/journal.pone.0247122
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-05T21:37:07.390Z
- SHA-256 of the archived text
876ff61b60e0fff503472ea0341f0992144d45cb26ac8fa9016535191f8b79de- Stable URL of this page
https://metraipolis.com/documento/dc_28e696b09cc3
How to cite
Observational study of haloperidol in hospitalized patients with COVID-19 — Europe PMC PMID:33606790 — Europe PMC (en), https://europepmc.org/article/MED/33606790 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_28e696b09cc3 (Metraipolis archive dc_28e696b09cc3, sha256 876ff61b60e0fff503472ea0341f0992144d45cb26ac8fa9016535191f8b79de)
BibTeX
@misc{dc28e696b09cc3,
title = {Observational study of haloperidol in hospitalized patients with COVID-19 — Europe PMC PMID:33606790},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/33606790},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_28e696b09cc3; sha256 876ff61b60e0fff503472ea0341f0992144d45cb26ac8fa9016535191f8b79de},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/33606790. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Background: Haloperidol, a widely used antipsychotic, has been suggested as potentially useful for patients with COVID-19 on the grounds of its in-vitro antiviral effects against SARS-CoV-2, possibly through sigma-1 receptor antagonist effect. Methods: We examined the associations of haloperidol use with intubation or death and time to discharge home among adult patients hospitalized for COVID-19 at Assistance Publique-Hôpitaux de Paris (AP-HP) Greater Paris University hospitals. Study baseline was defined as the date of hospital admission. The primary endpoint was a composite of intubation or death and the secondary endpoint was discharge home among survivors in time-to-event analyses. In the primary analyses, we compared these two outcomes between patients receiving and not receiving haloperidol using univariate Cox regression models in matched analytic samples based on patient characteristics and other psychotropic medications. Sensitivity analyses included propensity score analyses with inverse probability weighting and multivariable Cox regression models. Results: Of 15,121 adult inpatients with a positive COVID-19 PT-PCR test, 39 patients (0.03%) received haloperidol within the first 48 hours of admission. Over a mean follow-up of 13.8 days (SD = 17.9), 2,024 patients (13.4%) had a primary end-point event and 10,179 patients (77.6%) were discharged home at the time of study end on May 1st. The primary endpoint occurred in 9 patients (23.1%) who received haloperidol and 2,015 patients (13.4%) who did not. The secondary endpoint of discharge home occurred in 16 patients (61.5%) who received haloperidol and 9,907 patients (85.8%) who did not. There were no significant associations between haloperidol use and the primary (HR, 0.80; 95% CI, 0.39 to 1.62, p = 0.531) and secondary (HR, 1.30; 95% CI, 0.74 to 2.28, p = 0.355) endpoints. Results were similar in multiple sensitivity analyses. Conclusion: Findings from this multicenter observational study suggest that haloperidol use prescribed at a mean dose of 4.5 mg per day (SD = 5.2) for a mean duration of 8.4 days (SD = 7.2) may not be associated with risk of intubation or death, or with time to discharge home, among adult patients hospitalized for COVID-19. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2021 (prima pubblicazione 2021-02-19). Identificativi: PMID 33606790 · PMCID PMC7895415 · DOI 10.1371/journal.pone.0247122. Descrittori MeSH principali: Hospitalization; SARS-CoV-2. Pagina: https://europepmc.org/article/MED/33606790 — https://doi.org/10.1371/journal.pone.0247122. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-05T21:31:39.493Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.